Intervention not reported
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).
1 finding from 1 review
Intervention not reported
Worsening of clinical status: participants with new need for invasive mechanical ventilation or death at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes worsening of clinical status: participants with new need for… (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement of clinical status: participants discharged alive at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in improvement of clinical status: participants discharged alive at day… (low certainty).
1 finding from 1 review
Intervention not reported
QoL at longest · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes serious adverse events during the trial period (very low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in any adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at day 7 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in viral clearance at day 7 (low certainty).
1 finding from 1 review
Mortality at 30 days following the ingestion of paraquat · people with moderate to severe oral paraquat poisoning
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at final · people with moderate to severe oral paraquat poisoning
Glucocorticoid with cyclophosphamide plus usual care may leads to lower all‐cause mortality at final compared with usual care (with or without placebo) (low certainty).
2 findings from 1 review
New infection within 1 week after initiation of treatment Assessed through clinical diagnosis · people with moderate to severe oral paraquat poisoning
It is very uncertain whether glucocorticoid with cyclophosphamide plus usual care changes new infection within 1 week after initiation of treatment Assessed… compared with usual care (with or without placebo) (very low certainty).
1 finding from 1 review
Parasitaemia prevalence · People of all ages living in an area with moderate to high endemicity of P falciparum malaria (≥ 10% prevalence)
MDA showed no clear difference in parasitaemia prevalence compared with no MDA (low certainty).
1 finding from 1 review
Parasitaemia incidence · People of all ages living in an area with moderate to high endemicity of P falciparum malaria (≥ 10% prevalence)
MDA probably leads to lower parasitaemia incidence compared with no MDA (moderate certainty).
1 finding from 1 review
Confirmed malaria illness incidence · People of all ages living in an area with moderate to high endemicity of P falciparum malaria (≥ 10% prevalence)
MDA showed no clear difference in confirmed malaria illness incidence compared with no MDA (low certainty).
1 finding from 1 review
Participant‐reported pain intensity VAS (0‐10, lower score = less pain) · people with moderate to severe cancer pain
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – nausea compared with morphine (very low certainty).
1 finding from 1 review
Vomiting · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – vomiting compared with morphine (very low certainty).
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – dizziness compared with morphine (very low certainty).
1 finding from 1 review
Constipation · people with moderate to severe cancer pain
1 finding from 1 review
Quality of life · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with moderate to severe cancer pain
1 finding from 1 review